Home / Pharmaceuticals / Diabetes Drugs Market By Type Of Therapy (Insulin, Oral Hypoglycemic Drugs (Anti-Diabetes Drugs), Non-Insulin Injectable Anti-Diabetes Drugs, Others) - Growth, Future Prospects, And Competitive Analysis, 2017 - 2025

Diabetes Drugs Market By Type Of Therapy (Insulin, Oral Hypoglycemic Drugs (Anti-Diabetes Drugs), Non-Insulin Injectable Anti-Diabetes Drugs, Others) - Growth, Future Prospects, And Competitive Analysis, 2017 - 2025

Published: Nov 2017 | Report Code: 58812-11-17

Diabetes is a prolonged, enduring disease characterized by high blood glucose level arising when the pancreas are no longer capable to secrete insulin: a key hormone that processes glucose to produce energy. Inability to produce insulin or use it effectively leads to the raised glucose level in the blood (hyperglycemia). Over long term, high blood glucose level can damage the blood vessels in the heart, kidneys, eyes or the nervous system. The global diabetes drugs market is emerging at an impressive pace because of intensifying diabetes population leading to increasing demand for diabetic care. Apart from availability of an array of existing drugs, widespread R&D projects for new diabetes investigative methods has given industry a boost.

This research study titled ‘Diabetes Drugs Market – Growth, Future Prospects, and Competitive Analysis, 2017 – 2025’ states the detailed analysis which helps investors, developers, company executives and industry participants in making decisions related to the prospects in the global diabetes drugs market and to take strategic initiatives. This report examines and offers the foremost trends prevalent in the global diabetes drugs market and the market size and forecast.

The scope of the report comprises types of therapy and geographical distribution. The types of therapy segments are further categorized into insulin, oral hypoglycemic drugs (anti-diabetic drugs), non-insulin injectable anti-diabetes drugs, and others. In-depth analysis in terms of market size and forecast is done for each segment for the duration 2015-2025, alongside particular CAGRs for the duration 2017-2025 is also presented in the report.

The scope of this report also covers geographical segments along with major countries, which are alluded as follows:

  • North America
    • Canada
    • United States
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Rest of Middle East and Africa

Diabetes Drugs Market

A description of the market estimation of the above-mentioned segment for the duration 2015-2025 is covered in the scope of the report along with the individual market estimation for the respective countries in the regional segments.

A comprehensive description is also been presented regarding the market dynamics in the report to understand and anticipate the trends in the market. Tools for conducting a portfolio analysis by the key player are also demonstrated in the reports. This report also incorporates the company profiling of the major market players which holds the prominent position in the diabetes drugs market globally. The major players in global diabetes drugs market are AstraZeneca plc, Biocon Limited, Boston Therapeutics, Inc., Cadila Healthcare, Eli Lilly and Company, GlaxoSmithKline plc, Johnson & Johnson, Lupin Limited, Merck & Co., Inc., Novartis International AG, Pfizer, Inc., Ranbaxy Laboratories Limited, Sanofi S.A., Takeda Pharmaceutical Company Ltd., among others.

Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted

Chapter 2. Executive Summary
2.1. Global Diabetes Drugs Market Portraiture
2.1.1. Global Diabetes Drugs Market, by Type of Therapy, 2016 (US$ Bn)
2.1.2. Global Diabetes Drugs Market, by Geography, 2016 (US$ Bn)

Chapter 3. Diabetes Drugs: Market Dynamics and Outlook
3.1. Market Definition and Overview
3.2. Diabetes: Epidemiology
3.3. Drivers
3.4. Challenges
3.5. Opportunities
3.5.1. Attractive Investment Proposition, by Geography, 2016
3.6. Value Chain Analysis
3.7. Major Agreements, Partnerships and Collaborations
3.8. Competitive Landscape
3.8.1. Competitive Landscape, by Key Players, 2016

Chapter 4. Global Diabetes Drugs Market, by Type of Therapy, 2015 – 2025 (US$ Bn)
4.1. Overview
4.2. Attractive Investment Proposition, by Type of Therapy, 2016
4.3. Insulin
4.4. Oral Hypoglycemic Drugs (anti-diabetes drugs)
4.5. Non-insulin Injectable Anti-diabetes Drugs
4.6. Others
4.7. Phase III (Market estimations by 2025)
4.7.1. ISLETS (National Institute of Health (NID) & Health Resource and Services Administration)
4.7.2. ORMD-0801 or Placebo (Oramed, Ltd. & Integrium)
4.7.3. Tauroursodeoxycholic Acid (TUDCA) (Juvenile Diabetes Research Foundation)
4.7.4. Others
4.8. Tabular Presentation of Phase II (Qualitative Information)
4.9. Tabular Presentation of Phase Phase I (Qualitative Information)

Chapter 5. Global Diabetes Drugs Market, by Geography, 2015 – 2025
5.1. Overview
5.2. North America Diabetes Drugs Market Analysis, 2015 – 2025
5.2.1. North America Diabetes Drugs Market, by Type of Therapy, 2015 – 2025 (US$ Bn)
5.2.2. North America Diabetes Drugs Market, by Country, 2015 – 2025 (US$ Bn)
5.2.2.1. U.S.
5.2.2.2. Canada
5.3. Europe Diabetes Drugs Market Analysis, 2015 – 2025
5.3.1. Europe Diabetes Drugs Market, by Type of Therapy, 2015 – 2025 (US$ Bn)
5.3.2. Europe Diabetes Drugs Market, by Country, 2015 – 2025 (US$ Bn)
5.3.2.1. U.K.
5.3.2.2. Germany
5.3.2.3. France
5.3.2.4. Spain
5.3.2.5. Italy
5.3.2.6. Rest of Europe
5.4. Asia Pacific Diabetes Drugs Market Analysis, 2015 – 2025
5.4.1. Asia Pacific Diabetes Drugs Market, by Type of Therapy, 2015 – 2025 (US$ Bn)
5.4.2. Asia Pacific Diabetes Drugs Market, by Country, 2015 – 2025 (US$ Bn)
5.4.2.1. China
5.4.2.2. India
5.4.2.3. Japan
5.4.2.4. Rest of APAC
5.5. Latin America Diabetes Drugs Market Analysis, 2015 – 2025
5.5.1. Latin America Diabetes Drugs Market, by Type of Therapy, 2015 – 2025 (US$ Bn)
5.5.2. Latin America Diabetes Drugs Market, by Country, 2015 – 2025 (US$ Bn)
5.5.2.1. Brazil
5.5.2.2. Mexico
5.5.2.3. Rest of Latin America
5.6. Middle East & Africa (MEA) Diabetes Drugs Market Analysis, 2015 – 2025
5.6.1. MEA Diabetes Drugs Market, by Type of Therapy, 2015 – 2025 (US$ Bn)
5.6.2. MEA Diabetes Drugs Market, by Country, 2015 – 2025 (US$ Bn)
5.6.2.1. GCC
5.6.2.2. Rest of MEA

Chapter 6. Company Profiles
6.1.1. AstraZeneca plc
6.1.2. Business Description
6.1.3. Financial Information (Subject to data availability)
6.1.4. Application Portfolio
6.1.5. Key Developments
6.2. Biocon Limited
6.3. Boston Therapeutics, Inc.
6.4. Cadila Healthcare
6.5. Eli Lilly and Company
6.6. GlaxoSmithKline plc
6.7. Johnson & Johnson
6.8. Lupin Limited
6.9. Merck & Co., Inc.
6.10. Novartis International AG
6.11. Pfizer Inc.
6.12. Ranbaxy Laboratories Limited
6.13. Sanofi S.A.
6.14. Takeda Pharmaceutical Company Ltd.

List of Tables :

TABLE 1 Global Diabetes Drugs Market, by Type of Therapy, 2015 – 2025 (US$ Bn)
TABLE 2 Global Diabetes Drugs Market, by Geography, 2015 – 2025 (US$ Bn)
TABLE 3 North America Diabetes Drugs Market, by Type of Therapy, 2015 – 2025 (US$ Bn)
TABLE 4 North America Diabetes Drugs Market, by Geography, 2015 – 2025 (US$ Bn)
TABLE 5 Europe Diabetes Drugs Market, by Type of Therapy, 2015 – 2025 (US$ Bn)
TABLE 6 Europe Diabetes Drugs Market, by Geography, 2015 – 2025 (US$ Bn)
TABLE 7 Asia Pacific Diabetes Drugs Market, by Type of Therapy, 2015 – 2025 (US$ Bn)
TABLE 8 Asia Pacific Diabetes Drugs Market, by Geography, 2015 – 2025 (US$ Bn)
TABLE 9 Latin America Diabetes Drugs Market, by Type of Therapy, 2015 – 2025 (US$ Bn)
TABLE 10 Latin America Diabetes Drugs Market, by Geography, 2015 – 2025 (US$ Bn)
TABLE 11 Middle East and Africa Diabetes Drugs Market, by Type of Therapy, 2015 – 2025 (US$ Bn)
TABLE 12 Middle East and Africa Diabetes Drugs Market, by Geography, 2015 – 2025 (US$ Bn)
TABLE 13 AstraZeneca plc: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 14 Biocon Limited: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 15 Boston Therapeutics, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 16 Cadila Healthcare: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 17 Eli Lilly and Company: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 18 GlaxoSmithKline plc: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 19 Johnson & Johnson: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 20 Lupin Limited: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 21 Merck & Co., Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 22 Novartis International AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 23 Pfizer Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 24 Ranbaxy Laboratories Limited: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 25 Sanofi S.A.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 26 Takeda Pharmaceutical Company Ltd: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)

List of Figures :

FIG. 1 Diabetes Drugs: Market Segmentation
FIG. 2 Global Diabetes Drugs Market, by Type of Therapy, 2016 (US$ Bn)
FIG. 3 Global Diabetes Drugs Market, by Geography, 2016 (Value %)
FIG. 4 Attractive Investment Proposition, by Geography, 2016
FIG. 5 Value Chain Analysis: Global Diabetes Drugs Market
FIG. 6 Market Competition Landscape, by Key Players, 2016
FIG. 7 Global Insulin Market, 2015 – 2025 (US$ Bn)
FIG. 8 Global Oral hypoglycemic drugs (anti-diabetes drugs) Market, 2015 – 2025 (US$ Bn)
FIG. 9 Global Non-insulin injectable anti-diabetes drugs Market, 2015 – 2025 (US$ Bn)
FIG. 10 Global Other Diabetes Drugs Types Market, 2015 – 2025 (US$ Bn)
FIG. 11 U.S. Diabetes Drugs Market, 2015 – 2025 (US$ Bn)
FIG. 12 Canada Diabetes Drugs Market, 2015 – 2025 (US$ Bn)
FIG. 13 U.K. Diabetes Drugs Market, 2015 – 2025 (US$ Bn)
FIG. 14 Germany Diabetes Drugs Market, 2015 – 2025 (US$ Bn)
FIG. 15 France Diabetes Drugs Market, 2015 – 2025 (US$ Bn)
FIG. 16 Spain Diabetes Drugs Market, 2015 – 2025 (US$ Bn)
FIG. 17 Italy Diabetes Drugs Market, 2015 – 2025 (US$ Bn)
FIG. 18 Rest of Europe Diabetes Drugs Market, 2015 – 2025 (US$ Bn)
FIG. 19 China Diabetes Drugs Market, 2015 – 2025 (US$ Bn)
FIG. 20 India Diabetes Drugs Market, 2015 – 2025 (US$ Bn)
FIG. 21 Japan Diabetes Drugs Market, 2015 – 2025 (US$ Bn)
FIG. 22 Rest of Asia Pacific Diabetes Drugs Market, 2015 – 2025 (US$ Bn)
FIG. 23 Brazil Diabetes Drugs Market, 2015 – 2025 (US$ Bn)
FIG. 24 Mexico Diabetes Drugs Market, 2015 – 2025 (US$ Bn)
FIG. 25 Rest of Latin America Diabetes Drugs Market, 2015 – 2025 (US$ Bn)
FIG. 26 GCC Diabetes Drugs Market, 2015 – 2025 (US$ Bn)
FIG. 27 Rest of Middle East and Africa Diabetes Drugs Market, 2015 – 2025 (US$ Bn)

Based on the type of therapy, global diabetes drugs market is segmented as follows:

  • Insulin
  • Oral hypoglycemic drugs (anti-diabetes drugs)
  • Non-insulin injectable anti-diabetes drugs 
  • Others

Diabetes Drugs Market

In 2016, insulin dominated the market due to continuous market entry of novel drug therapies, most convenient mode of treatment, and rising demand for targeted therapy/biological drugs. The growth of diabetes drugs market has been strongly supported by novel drug therapies like anti-diabetes drugs and more. One major factor that contributes to the growth of diabetes drugs is increased life expectancy. As the populations are rapidly aging, the incidence and prevalence of many chronic diseases degeneration are bound to increase correspondingly, thus driving the growth in demand for diabetes drugs. Additionally, it is not just geriatric population that is making the choice for diabetes drugs, but increasing incidence is also being noticed in adolescents, which is also supporting the growth of the market.

Diabetes medicine is a general treatment for the people who are suffering from diabetes. Various types of diabetes or anti-diabetes drugs are available, having their own area of action which help the patient to keep the condition under control. The way of delivery may differ, some injected directly into blood and some drugs taken orally. The global diabetes drugs market is emerging at impressive pace because of intensifying diabetic population growth, aging, unhealthy diets, obesity, and sedentary lifestyle resulting in increasing demand for diabetic drugs and enhancing the market size.

Geographically, the global diabetes drugs market is cumulative to Europe, North America, Asia Pacific, Middle East and Africa and Latin America.

Diabetes Drugs Market

In 2016, North America & Europe have accounted for the major share in global diabetes drugs market followed by Asia Pacific due to key driving factors such as rising prevalence of diabetes, high awareness associated with early diabetes diagnosis and treatment, and supportive reimbursement policies. The International Diabetes Federation estimates that in 2017 about 82 million people were diagnosed in Asia Pacific and about 1.1 million deaths occurred. Due to perpetual growth in incidence of diabetes, the demand for novel drug therapies are expected to increase in the near future. During forecast period 2017 – 2025, Asia Pacific was observed as the fastest growing region due to key driving factors such as rising prevalence of diabetes in developing countries, increasing awareness associated with early diabetes diagnosis, developing healthcare infrastructure, and mounting demand for novel drug therapies.

The detailed geographical classification of the global diabetes drugs market is as follows:

  • North America (U.S. & Canada)
  • Asia Pacific (Japan, India, China, and Rest of Asia Pacific)
  • Europe (France, Germany, U.K., Spain, Italy, and Rest of Europe)
  • Latin America (Mexico, Brazil, and Rest of Latin America)
  • Middle East and Africa (GCC and Rest of Middle East and Africa)
Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Credence Webinars

Join Credence analysts to explore the latest IT Trends

view upcoming webinars

Our Clients